Here, we investigated in an experimental murine model of Graves’ disease, whether autoimmune GD and TED associates with bone marrow activation and whether linsitinib, an oral small molecule inhibitor of the IGF-1R and insulin receptor (IR), interferes with this activation process. Here, IGF1R is linked to Graves disease.